Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Relistor

Medius Deal Watch table for February 2015

The top major pharma mergers, acquisitions and collaborations during the month were led by the Pfizer/Hospira and Salix/Valeant deals

- PMLiVE

AZ and Takeda drugs should carry heart failure warning

FDA panel claim diabetes drugs Onglyza and Nesina need label updates

- PMLiVE

Takeda’s once-weekly DPP-4 inhibitor cleared in first market

Zafatek’s authorisation one of a flurry of new approvals for a number of firms in Japan

- PMLiVE

Takeda spends $230m on oncology biotech deal

Buys into ImmunoGen’s antibody-drug conjugate technology

- PMLiVE

Valeant raises offer for Salix; rival Endo bows out

Has increased bid to $173 per share in cash

- PMLiVE

Takeda’s Entyvio recommended by NICE for bowel disease

But must supply the drug at a discounted rate to the NHS

- PMLiVE

Endo tries to ride out Valeant with $15.7bn bid for Salix

Around $1.2bn more than rival bid

Takeda appoints Christophe Weber as its new CEO

Frenchman had been widely expected to succeed Yasuchika Hasegawa

- PMLiVE

Amgen’s Kyprolis tops Velcade in myeloma trial

Amgen hoping to topple Takeda’s $2bn a year drug

- PMLiVE

Takeda grows in Turkey with Neutec subsidiary acquisition

Will acquire Toplam Kalite for up to 300m Turkish lira

- PMLiVE

Valeant swoops on Salix with $10bn takeover deal

Firm will also absorb Salix’s $4.6bn debt, adding to its existing $15bn

- PMLiVE

Takeda’s lung cancer drug motesanib flunks another trial

Drug was unable to extend progression-free survival in study of 400 patients

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links